INTRODUCTION
Approximately 20% of classical Hodgkin's lymphoma (cHL) patients are older than 60 years. 1 Their survival is inferior compared with younger patients despite similar treatments. 2 These disappointing results are attributed to several factors, such as a greater number of co-morbidities, poor performance status, different histological and biological features, lower chemotherapy doses and more toxicity with an increased related mortality rate for the oldest patients. As mentioned, elderly patients experience more refractory or relapsed (R/R) disease, and the German Hodgkin Study Group has reported a series of 105 R/R cHL patients treated in its trials and concluded that 'the poor outcome of high-risk patients based on time to relapse, clinical stage and anemia, cannot be overcome by any strategies including high-dose chemotherapy'. 3 For R/R cHL young patients, autologous stem cell transplantation (ASCT) is a standard of care after salvage chemotherapy, leading to increased disease-free survival 4, 5 and some reports of ASCT in elderly patients with other hematological malignancies, such as multiple myeloma or non-Hodgkin's lymphoma, have been published 6, 7 with acceptable toxicity. However, only a few studies have examined ASCT in elderly patients (⩾60 years) with R/R HL. 8 To assess this treatment option, we retrospectively analyzed the efficacy and toxicity of high-dose chemotherapy followed by ASCT in 91 patients with R/R cHL recorded in the SFGM-TC database and correlated survival with well-known prognostic factors.
PATIENTS AND METHODS Patients
Between January 1992 and December 2012, 128 patients aged 60 years or older with R/R cHL underwent ASCT, and were recorded in the SFGM-TC database. Specific study questionnaires were sent to transplant centers to obtain comprehensive, updated data regarding disease characteristics at diagnosis and at the time of ASCT, as well as relapse or progression. Thirtyseven patients were excluded from the analysis, because of lack of information about initial treatment, salvage chemotherapy and the conditioning regimen. The other 91 patients are analyzed in the current report despite some missing data highlighted in the tables. This study was approved by the scientific committee of the SFGM-TC, and is in accordance with the Declaration of Helsinki for clinical research.
Statistical methods
Disease extent was defined according to the Ann Arbor staging classification, which is based on clinical examination, computed tomography, bone marrow biopsy and for some patients FDG-PET from 2001.
CR was defined as the total disappearance of all evidence of the disease at 3 months restaging after the end of treatment. A PR was defined as a reduction of 450% in tumor volume. Treatment failure was defined as a reduction of o50% in tumor volume. Primary refractory HL was defined as disease that progressed although the patient was receiving initial chemotherapy or within 3 months after the completion of the treatment. Response and relapse were defined according to Cheson criteria 1999 9 and 2007. 10 Overall survival (OS) was calculated from the time of ASCT to death from any cause or last patient follow-up. PFS was calculated from the time of ASCT until disease progression, relapse and death from any cause or last patient follow-up. Both OS and PFS were estimated using the Kaplan and Meier method, and compared with the log-rank test.
Correlation between G-CSF use and post-transplant toxicity was assessed using Fisher's exact test. The impact of G-CSF use on hematological recovery and length of hospitalization stay were independently assessed using Mann-Whitney U tests. Any statistical test yielding a P-value o 5% was considered as significant.
RESULTS

Patient characteristics
Patient characteristics at diagnosis including missing data are summarized in Table 1 . Median age was 61 years (range: 46-69 years). Among patients with available data, men and nodular sclerosis histology were more commonly noted, the majority of patients had advanced stage, B-symptoms, and at least one comorbidity according to the Charlson11 score and few patients (2/51) disclosed a poor performance status Eastern Cooperative Oncology Group (ECOG)41. The overall response rate after the first-line chemotherapy regimen was 80%. CR was noted in 53% of patients (48 patients). Unconfirmed CR (CRu) was noted in 4% of patients (4 patients), and PR was observed in 23% of patients (21 patients).
Patient's characteristics at salvage chemotherapy are detailed in Table 2 .
Salvage chemotherapy
The most frequent salvage chemotherapy used before ASCT was Mine R (mitoguazone, ifosfamide, vinorelbine and etoposide) (32%) 11 followed by DHAP (dexamethasone, cytarabine and cisplatin)/DHAOx 12 (dexamethasone, L-OHP and cytarabine) (18%) and ifosfamide-based chemotherapy (IVA (ifosfamide, etoposide and doxorubicin)+ICE (ifosfamide, carboplatin and etoposide)) 12 (18%). Other salvage chemotherapeutic regimens were used in 10% of patients, and in 22% patients, the regimen was not specified. The median number of salvage chemotherapeutic regimens was 2 (1-4). Fifty-two patients were treated with one or two chemotherapy lines, whereas 21 patients received at least three chemotherapy lines. The majority of patients were chemosensitive with an overall response rate before ASCT of 96% (CR/CRu: 57 patients+PR: 30 patients) Evaluations were performed via PET scan in 61 patients (67%) and computed tomography (CT) scan in 16 patients. (Table 2) Autologous stem cell transplantation At transplantation, the median age was 63 years (range: 60-75). The majority of patients (62/64) had a good performance status (ECOG ⩽ 2) ( Table 2) , and was transplanted after 2001 (78/91).
The median time between diagnosis and transplantation was 19 months (range: 4-239), and 30 patients were transplanted within 1 year of diagnosis (33%). The conditioning regimen was BEAM (BCNU 300 mg/m 2 at day − 7, cytarabine 200 mg/m 2 from day − 6 to − 3, etoposide 200 mg/m 2 from day − 6 to − 3, melphalan 140 mg/m 2 at day − 2) in 93% of patients (84 /91). Abbreviations: ABVD = adriamycin, bleomycin, vinblastine and dacarbazine; BEACOPP = bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone; CRu = unconfirmed complete response; MOPP = mechlorethamine, vincristine, procarbazine and prednisone; OR = overall response; PD = progressive disease; PVAG = prednisone, vinblastine, doxorubicin and gemcitabine; SD = stable disease; Stanford V = mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide and prednisone; VABEM = vindesine, doxorubicin, carmustine, etoposide and methylprednisolone.
The majority of patients were transplanted with PBSC (98%: 89/91 patients); the remaining two patients received bone marrow stem cells. The median number of reinfused CD34+ cells was 4. 2 10 6 /kg (range: 0.9-17.8) ( Table 3) .
Hematopoietic engraftment, toxicity and outcome After transplantation, 52 patients received G-CSF support. The median time to achieve a neutrophil count 41 × 10 9 /L and a platelet count 420 × 10 9 /L was 11 days (range: 8-104) and 13 days (range: 7-115), respectively.
The median duration of hospitalization was 22 days (8-49). Early grade 3-4 toxicities occurred in 24 patients (26%) and are detailed in Table 3 . There was no difference in terms of post-transplant toxicity, hematological recovery or length of hospitalization stay between patients that received or not G-CSF.
With a median follow-up from ASCT of 54 months (range: 1-185) for the entire group, the 5-year estimate OS (Figure 1 ) and PFS ( Figure 2 ) were 67% (95% confidence interval: 56-80%) and 54% (95% confidence interval: 43-68%), respectively. In univariate (Table 4) . We also investigated the influence of age (60-65 versus 465) (P = 0.43), time to relapse (⩽1 year versus 41 year) (P = 0.63), hemoglobin level (hemoglobin level o 10.5 g/dL in women and o 12.0 g/dL in men) (P = 0.61) on OS. In spite of missing data, the number of salvage chemotherapy lines before ASCT (1-2 versus ⩾ 3) was the only factor that significantly impacts the OS but not the PFS (Table 4 ). All the R/R patients treated with more than three lines of chemotherapy before ASCT (4 patients) died from HL. Thirteen patients (14%) relapsed with a median delay of 5 months (range: 4-52) with six (7%) early relapses occurring o3 months after ASCT.
Twenty-six patients died at a median time of 18 months (range: 0-136). Among the patients who died within the year of transplantation, six patients (6.6%) died from early toxicity, one from interstitial pneumonia, one from heart failure and one from multi-organ failure. The causes of deaths are detailed in Table 5 .
DISCUSSION
Twenty percent of cHL patients are aged 60 years or older. 1 Their survival rates are inferior to those of younger patients (5-year survival rates of 50 versus 80%, respectively) for several reasons, including disease features, lower delivery of standard chemotherapy and excessive toxicity. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] No standard of care is available for first 14 or additional lines of chemotherapy for this age group. ASCT is a usual treatment in R/R cHL young patients. 4, 5 However, little is known regarding ASCT in R/R cHL in elderly patients (⩾60 years), even if this procedure is well tolerated in other hematological malignancies, such as multiple myeloma or non-Hodgkin lymphoma. 6, 7 This retrospective study based on data collected in the SFGM-TC registry analyzed 91 consecutive R/R cHL patients aged ⩾ 60 years at the moment of transplantation. This study provides information about the efficacy and toxicity of this treatment in elderly patients.
In terms of efficacy, the long follow-up of our series allows a good estimation of survival and late events. In our study, the 6-year OS was 64%. This value is lower than that reported in the Puig et al. (88%) 8 series, but in this series, only 15 elderly patients were analyzed with a median follow-up of 2.5 years. However, similar to our study, only transplanted patients were analyzed. Thus, some bias could be present and interfere with the outcome. Questions regarding high-dose chemotherapy and ASCT are partially discussed by Boll et al. 3 In their report, only 5 patients among the 23 high-risk patients underwent ASCT, and they concluded that OS did not differ from other treatment strategies in high-risk patients. The poor prognosis of these patients with adverse prognostic factors could eventually explain the low number of patients transplanted in this setting.
None of the prognostic factors at relapse described by Josting et al. 15 (hemoglobin level o10.5 g/dL in women and o 12.0 g/dL in men, stage III or IV at relapse, early relapse o 12 months after the end of first-line treatment) was significantly predictive of survival in our study. But once again the missing data could partly explain this observation. Otherwise, different adverse risk factors have also been published to predict PFS after ASCT in cHL, 16 including Karnofsky performance score o90 at transplantation, chemotherapy resistance, at least three chemotherapy regimens pretransplantation, extra-nodal disease and the presence of residual disease, 17 and B-symptoms at pretransplant relapse. 18 Unfortunately, apart from the number of pretransplantation chemotherapy lines, ECOG and response to salvage chemotherapy, the other parameter, extra-nodal disease, was not collected in our study and could not be assessed. These three parameters were not significantly predictive of PFS even if a trend could be noted for number of pre-transplant chemotherapy lines which significantly impacted OS. This point stressed the importance of salvage chemotherapy to induce rapid remission and transplantation, and to avoid cumulative toxicity before and after ASCT. Once again, missing data preclude any satisfactory explanation and conclusion. A majority of patients was evaluated with PET scan and transplanted with a good response (96%). In recent years, a negative PET scan 19 before transplantation appeared as a strong factor to predict PFS and OS. However, no significant correlation could be established in our series.
The toxicity of ASCT has been improved during recent years, even in older patients. 20 In our series, hematopoietic engraftment and extra-hematopoietic toxicities (mainly mucositis) compared favorably to other series. 8 A high proportion of patients received G-CSF support after transplant, which could explain the low level of infection but no significant correlation could be observed between the use of G-CSF and neutrophil recovery, toxicity and length of hospitalization. Early mortality ( o3 months) was related to transplant procedures in 3% of patients (for three patients the cause of death was not specified). This death rate is similar to the Abbreviations: cHL = classical Hodgkin lymphoma; EBV LP = EBV lymphoproliferative disease; MOF = multi-organ failure.
rate described in elderly transplanted patients with non-Hodgkin lymphoma. 21 HL was the cause of death in 6.6%, occurring during the first year after transplantation.
The question of transplantation in the era of new agents should be discussed. Indeed, brentuximab vedotin has demonstrated efficacy in R/R cHL with some reports of long lasting CR. 22 This drug is presently considered as a bridge to other therapies, including transplantation. Furthermore, in post-transplant use, this drug has demonstrated a benefit in term of PFS. 23 The main limitation of this retrospective study is that the analysis was exclusively performed with selected transplanted patients, and we do not know the proportion of patients with R/R cHL who could not be transplanted whatever the reason. The second limit is the proportion of missing data before transplantation, which impacts the search for possible correlations particularly regarding prognostic factors, and the interpretation of these results.
Nevertheless, despite its limitations, this retrospective study with long-term follow-up suggests that ASCT is a valid treatment option for elderly chemosensitive R/R cHL patients with an acceptable rate of toxicity, thus warranting further investigations in the era of novel agents, such as brentuximab. The rate of missing data in this study leads us to propose prospective studies in this age group with specific tools, including a geriatric evaluation and a metabolic response evaluation with a PET scan.
